Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women

Garrett Scott, Samuel Chi-Hung Yiu, Daniel Wasilewski, Jonathan Song, Ronald E. Smith

Research output: Contribution to journalArticle

Abstract

PURPOSE: To determine whether systemic replacement with combined esterified estrogen (EE) and methyltestosterone (MT) (EE + MT) would reduce symptoms and promote clinical improvement in postmenopausal women with dry eye syndrome (DES). DESIGN: Retrospective, noncomparative, interventional case series. METHODS: Investigators reviewed the charts of 11 postmenopausal women treated within the last 3 years with EE + MT. RESULTS: The mean patient age was 65.2 years (standard deviation [SD] 11.4, range 48-84 years). The mean treatment duration was 12.2 months (SD 6.2 months, range 4-24 months). Ten (91%) of 11 patients reported improvement in dry eye symptoms while receiving treatment. For these 10, relief occurred after an average of 4.1 months of treatment (SD 3.2, range, 1-9 months). CONCLUSIONS: Treatment with EE + MT may be efficacious for DES of various etiologies. A randomized placebo-controlled trial is planned to further evaluate these encouraging findings.

Original languageEnglish (US)
Pages (from-to)1109-1110
Number of pages2
JournalAmerican Journal of Ophthalmology
Volume139
Issue number6
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Dry Eye Syndromes
Methyltestosterone
Estrogens
Therapeutics
Randomized Controlled Trials
Placebos
Research Personnel

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women. / Scott, Garrett; Yiu, Samuel Chi-Hung; Wasilewski, Daniel; Song, Jonathan; Smith, Ronald E.

In: American Journal of Ophthalmology, Vol. 139, No. 6, 06.2005, p. 1109-1110.

Research output: Contribution to journalArticle

Scott, Garrett ; Yiu, Samuel Chi-Hung ; Wasilewski, Daniel ; Song, Jonathan ; Smith, Ronald E. / Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women. In: American Journal of Ophthalmology. 2005 ; Vol. 139, No. 6. pp. 1109-1110.
@article{b677804317104249aebdfc3c0fd58cfc,
title = "Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women",
abstract = "PURPOSE: To determine whether systemic replacement with combined esterified estrogen (EE) and methyltestosterone (MT) (EE + MT) would reduce symptoms and promote clinical improvement in postmenopausal women with dry eye syndrome (DES). DESIGN: Retrospective, noncomparative, interventional case series. METHODS: Investigators reviewed the charts of 11 postmenopausal women treated within the last 3 years with EE + MT. RESULTS: The mean patient age was 65.2 years (standard deviation [SD] 11.4, range 48-84 years). The mean treatment duration was 12.2 months (SD 6.2 months, range 4-24 months). Ten (91{\%}) of 11 patients reported improvement in dry eye symptoms while receiving treatment. For these 10, relief occurred after an average of 4.1 months of treatment (SD 3.2, range, 1-9 months). CONCLUSIONS: Treatment with EE + MT may be efficacious for DES of various etiologies. A randomized placebo-controlled trial is planned to further evaluate these encouraging findings.",
author = "Garrett Scott and Yiu, {Samuel Chi-Hung} and Daniel Wasilewski and Jonathan Song and Smith, {Ronald E.}",
year = "2005",
month = "6",
doi = "10.1016/j.ajo.2004.11.042",
language = "English (US)",
volume = "139",
pages = "1109--1110",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women

AU - Scott, Garrett

AU - Yiu, Samuel Chi-Hung

AU - Wasilewski, Daniel

AU - Song, Jonathan

AU - Smith, Ronald E.

PY - 2005/6

Y1 - 2005/6

N2 - PURPOSE: To determine whether systemic replacement with combined esterified estrogen (EE) and methyltestosterone (MT) (EE + MT) would reduce symptoms and promote clinical improvement in postmenopausal women with dry eye syndrome (DES). DESIGN: Retrospective, noncomparative, interventional case series. METHODS: Investigators reviewed the charts of 11 postmenopausal women treated within the last 3 years with EE + MT. RESULTS: The mean patient age was 65.2 years (standard deviation [SD] 11.4, range 48-84 years). The mean treatment duration was 12.2 months (SD 6.2 months, range 4-24 months). Ten (91%) of 11 patients reported improvement in dry eye symptoms while receiving treatment. For these 10, relief occurred after an average of 4.1 months of treatment (SD 3.2, range, 1-9 months). CONCLUSIONS: Treatment with EE + MT may be efficacious for DES of various etiologies. A randomized placebo-controlled trial is planned to further evaluate these encouraging findings.

AB - PURPOSE: To determine whether systemic replacement with combined esterified estrogen (EE) and methyltestosterone (MT) (EE + MT) would reduce symptoms and promote clinical improvement in postmenopausal women with dry eye syndrome (DES). DESIGN: Retrospective, noncomparative, interventional case series. METHODS: Investigators reviewed the charts of 11 postmenopausal women treated within the last 3 years with EE + MT. RESULTS: The mean patient age was 65.2 years (standard deviation [SD] 11.4, range 48-84 years). The mean treatment duration was 12.2 months (SD 6.2 months, range 4-24 months). Ten (91%) of 11 patients reported improvement in dry eye symptoms while receiving treatment. For these 10, relief occurred after an average of 4.1 months of treatment (SD 3.2, range, 1-9 months). CONCLUSIONS: Treatment with EE + MT may be efficacious for DES of various etiologies. A randomized placebo-controlled trial is planned to further evaluate these encouraging findings.

UR - http://www.scopus.com/inward/record.url?scp=20444472723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444472723&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2004.11.042

DO - 10.1016/j.ajo.2004.11.042

M3 - Article

C2 - 15953447

AN - SCOPUS:20444472723

VL - 139

SP - 1109

EP - 1110

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 6

ER -